{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-151963","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.399340+00:00","generated_at":"2026-06-01T07:07:43.645093+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CFO Edward J. Dulac III resigns; CEO J. Scott Wolchko to assume CFO role effective June 14, 2024","bullets":["Edward J. Dulac III resigned as CFO voluntarily, effective June 14, 2024; no disagreement with the company.","CEO J. Scott Wolchko will succeed Dulac as CFO and principal financial/accounting officer immediately after resignation.","Wolchko previously served as CFO from company inception until August 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-151963","json":"https://secwatch.observer/filing/0001193125-24-151963.json","markdown":"https://secwatch.observer/filing/0001193125-24-151963.md","text":"https://secwatch.observer/filing/0001193125-24-151963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/d845254d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:07:43.645093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f8ab85f69","claim":"J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.","evidence_excerpt":"The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"717da89d09","claim":"Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.","evidence_excerpt":"On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524151963/0001193125-24-151963-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}